-
Zafgen Shares Surge On Positive Phase 3 Trial
Monday, April 4, 2016 - 8:06am | 329Read More...Shares of Zafgen Inc (NASDAQ: ZFGN) gained more than 14 percent early Monday morning after the company announced positive data from a Phase 3 trial evaluating the safety and efficacy of beloranib. The study evaluated the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with...
-
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
Monday, August 31, 2015 - 1:31pm | 362Read More...Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...
-
FDA Delays Decision on Amarin's Vascepa Drug
Friday, December 20, 2013 - 1:46pm | 611Read More...The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga, Amarin was waiting to hear the results of a Food and Drug Administration ruling. The company had appealed the FDA's October...
